1128P - CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Biomarkers
Melanoma and other Skin Tumours
Presenter Laura Orgiano
Citation Annals of Oncology (2016) 27 (6): 379-400. 10.1093/annonc/mdw379
Authors L. Orgiano1, F. Bruder2, C. Madeddu1, R. Marconcini3, E. Gambale4, E. Galizia5, S. Stucci6, F. Spagnolo7, L. Di Guardo8, C. Loi2, F. Pani9, D. Massa2, E. Massa1, G. Astara1, M. Del Vecchio8, F. Silvestris6, M. de tursi4, A. Falcone3, P. Queirolo7, M. Scartozzi1
  • 1Medical Oncology, Azienda Ospedaliero Universitaria di Cagliari, 09042 - Monserrato/IT
  • 2Medical Oncology, Ospedale Oncologico "A. Businco", 09100 - Cagliari/IT
  • 3Dept. Of Oncology-presidio Ospedaliero, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 4Department Of Medical Oncology, AOU Chieti, Chieti/IT
  • 5Medical Oncology, Ospedale E. Profili U.O. Oncologia Medica, Fabriano/IT
  • 6Department Of Medical Oncology, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Department of Medical Oncology - Bari/IT
  • 7Medical Oncology, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova/IT
  • 8Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano/IT
  • 9Department Of Medical Sciences, Endocrinology Unit, University of Cagliari, Cagliari/IT

Abstract

Background

Ipilimumab is an inhibitor of CTLA4 receptor of T lymphocytes approved by the FDA both as first and second line treatment for patients with metastatic melanoma. Despite the efficacy observed in about 20% of patients, it still remains a therapy with a considerable outlay, both from an economic and safety point of view: the aim of our study was to explore prognostic biomarkers among hematological parameters normally used in clinical practice.

Methods

This is a retrospective multicenter study which enrolled 120 patients with hystologically confirmed metastatic melanoma treated with Ipilimumab between January 2013 and January 2016 (mean age 62.2 ± 14.58). Full blood count with absolute WBC (aWBC), neutrophil count, eosinophil count, neutrophil/lymphocyte ratio (NLR), platelets/lymphocyte ratio (PLR) and LDH serum levels were assessed at baseline and every 3 weeks during treatment. We evaluated the mutational BRAF status and the number of metastatic sites involved before treatment (more or less than 3 sites). The cut-off values for our parameters were determined with time-dependent receiver operating characteristic (ROC) analysis. To identify prognostic and predictive biomarkers the above parameters have been correlated with Progression-Free Survival (PFS) and Overall Survival (OS).

Results

After a median follow up of 21 months, median PFS was 4 months and median OS was 17 months. Patients with low serum LDH levels at baseline had significantly longer PFS (p = 0.018) and OS (p 

Conclusions

Although these findings need to be confirmed and validated and the multivariate analysis is still in progress, we suggest that the parameters explored in our study, which are normally assessed in clinical practice, may be useful to assist disease-management strategies for advanced melanoma patients.

Clinical trial identification

Legal entity responsible for the study

Prof. Mario Scartozzi, AOU Cagliari

Funding

Prof. Mario Scartozzi, AOU Cagliari

Disclosure

All authors have declared no conflicts of interest.